Format

Send to

Choose Destination
J Nucl Med. 2014 Sep;55(9):1473-80. doi: 10.2967/jnumed.114.139626. Epub 2014 Jul 28.

18F-FDG PET and MR imaging associations across a spectrum of pediatric brain tumors: a report from the pediatric brain tumor consortium.

Author information

1
Department of Medical Imaging, Sunnybrook Health Sciences Centre, University of Toronto, Ontario, Canada Department of Radiology, Harvard Medical School, Boston, Massachusetts.
2
Department of Radiology, Harvard Medical School, Boston, Massachusetts Department of Radiology, Boston Children's Hospital, Boston, Massachusetts.
3
Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis, Tennessee.
4
Department of Radiological Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee.
5
Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee; and.
6
Department of Hematology/Oncology, Cincinnati Children's Medical Center, Cincinnati, Ohio.
7
Department of Radiology, Harvard Medical School, Boston, Massachusetts Department of Radiology, Boston Children's Hospital, Boston, Massachusetts tinayoung.poussaint@childrens.harvard.edu.

Abstract

The purpose of this study was to describe (18)F-FDG uptake across a spectrum of pediatric brain tumors and correlate (18)F-FDG PET with MR imaging variables, progression-free survival (PFS), and overall survival (OS).

METHODS:

A retrospective analysis was conducted of children enrolled in phase I/II clinical trials through the Pediatric Brain Tumor Consortium from August 2000 to June 2010. PET variables were summarized within diagnostic categories using descriptive statistics. Associations of PET with MR imaging variables and PFS and OS by tumor types were evaluated.

RESULTS:

Baseline (18)F-FDG PET was available in 203 children; 66 had newly diagnosed brain tumors, and 137 had recurrent/refractory brain tumors before enrolling in a Pediatric Brain Tumor Consortium trial. MR imaging was performed within 2 wk of PET and before therapy in all cases. The (18)F-FDG uptake pattern and MR imaging contrast enhancement (CE) varied by tumor type. On average, glioblastoma multiforme and medulloblastoma had uniform, intense uptake throughout the tumor, whereas brain stem gliomas (BSGs) had low uptake in less than 50% of the tumor and ependymoma had low uptake throughout the tumor. For newly diagnosed BSG, correlation of (18)F-FDG uptake with CE portended reduced OS (P = 0.032); in refractory/recurrent BSG, lack of correlation between (18)F-FDG uptake and CE suggested decreased PFS (P = 0.023). In newly diagnosed BSG for which more than 50% of the tumor had (18)F-FDG uptake, there was a suggestion of lower apparent diffusion coefficient (P = 0.061) and decreased PFS (P = 0.065).

CONCLUSION:

(18)F-FDG PET and MR imaging showed a spectrum of patterns depending on tumor type. In newly diagnosed BSG, the correlation of (18)F-FDG uptake and CE suggested decreased OS, likely related to more aggressive disease. When more than 50% of the tumor had (18)F-FDG uptake, the apparent diffusion coefficient was lower, consistent with increased cellularity. In refractory/recurrent BSG, poor correlation between (18)F-FDG uptake and CE was associated with decreased PFS, which may reflect concurrent tissue breakdown at sites of treated disease and development of new sites of (18)F-FDG-avid malignancy.

KEYWORDS:

18F-FDG PET; MR diffusion; brain tumor; pediatric

PMID:
25071098
PMCID:
PMC4249729
DOI:
10.2967/jnumed.114.139626
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center